Health Catalyst, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Health Catalyst, Inc. on March 24, 2023, with the earliest event reported on that date. The filing discloses significant changes in the Company's executive leadership structure, specifically regarding the Chief Operating Officer, Chief Product Officer, General Counsel, and Corporate Secretary roles.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes rather than financial performance.
Material Changes
- COO and CPO Appointment: Anne Marie Bickmore, previously Chief Product Officer since March 2021, will assume the additional role of Chief Operating Officer effective April 3, 2023. She has been with the Company since December 2012.
- General Counsel Resignation: Daniel Orenstein will step down as General Counsel and Corporate Secretary effective April 30, 2023. He will transition to a Senior Advisor role under an independent contractor agreement to ensure a smooth handover. The departure is not due to any disagreement with the Company.
- General Counsel Appointment: Benjamin Landry, currently Assistant General Counsel since July 2019, will be appointed General Counsel and Corporate Secretary effective May 1, 2023.
Outlook, Risks, and Contingencies
The Company expects to enter into an indemnification agreement with Ms. Bickmore and anticipates her participation in the Executive Severance Plan. No material conflicts of interest or family relationships were disclosed regarding these appointments. The transition of the General Counsel role is structured to maintain continuity through Mr. Orenstein's advisory capacity.
Key Facts for Investor Verification
- Verify the effective dates of leadership transitions: April 3, 2023 (Bickmore) and May 1, 2023 (Landry).
- Confirm the terms of the independent contractor agreement for the outgoing General Counsel, Daniel Orenstein.
- Review the Company's Executive Severance Plan and Indemnification Agreement referenced in the exhibits.
- Note that this filing contains no financial data; refer to the most recent 10-Q or 10-K for financial metrics.